Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM2 | Q9P1W9 | 20/20 | 0.58 |
| ▸ | PIM1 | P11309 | 19/20 | 0.58 |
| ▸ | PIM3 | Q86V86 | 18/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17136290 | 0.88 | PIM1 (0.57) | PIM2PIM1PIM3 | |
| SCHEMBL17136313 | 0.88 | PIM1 (0.52) | PIM2PIM1PIM3 | |
| Hydrochloric Acid SCHEMBL18695485 | 0.87 | PIM1 (0.51) | PIM2PIM1PIM3 | |
| SCHEMBL17136310 | 0.86 | PIM2 (0.58) | PIM2PIM1PIM3 | |
| SCHEMBL18659480 | 0.85 | PIM1 (0.46) | PIM2PIM1PIM3 | |
| SCHEMBL17136331 | 0.84 | PIM1 (0.65) | PIM2PIM1PIM3 | |
| Hydrochloric Acid SCHEMBL18695479 | 0.84 | PIM1 (0.46) | PIM2PIM1PIM3 | |
| SCHEMBL17136089 | 0.83 | PIM2 (0.47) | PIM2PIM1PIM3 | |
| SCHEMBL17136302 | 0.82 | PIM1 (0.54) | PIM2PIM1PIM3 | |
| Hydrochloric Acid SCHEMBL18695506 | 0.81 | PIM1 (0.53) | PIM2PIM1PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452995-B2 | Pyridine derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof | Jikai Biosciences, Inc. (CN) | 2016-09-27 | — | — | US | claimed |
| US-20150284363-A1 | PYRIDINE DERIVATIVES AS PIM KINASE INHIBITORS AND PREPARATION METHODS AND USE IN MEDICINAL MANUFACTURE THEREOF | Jikai Biosciences, Inc. | 2015-10-08 | — | — | US | claimed |
| US-9452995-B2 | Pyridine derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof | Jikai Biosciences, Inc. (CN) | 2016-09-27 | — | — | US | disclosed |
| US-9452995-B2 | Pyridine derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof | Jikai Biosciences, Inc. (CN) | 2016-09-27 | — | — | US | disclosed |
| US-9452995-B2 | Pyridine derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof | Jikai Biosciences, Inc. (CN) | 2016-09-27 | — | — | US | disclosed |
| US-20150284363-A1 | PYRIDINE DERIVATIVES AS PIM KINASE INHIBITORS AND PREPARATION METHODS AND USE IN MEDICINAL MANUFACTURE THEREOF | Jikai Biosciences, Inc. | 2015-10-08 | — | — | US | disclosed |
| US-20150284363-A1 | PYRIDINE DERIVATIVES AS PIM KINASE INHIBITORS AND PREPARATION METHODS AND USE IN MEDICINAL MANUFACTURE THEREOF | Jikai Biosciences, Inc. | 2015-10-08 | — | — | US | disclosed |
| US-20150284363-A1 | PYRIDINE DERIVATIVES AS PIM KINASE INHIBITORS AND PREPARATION METHODS AND USE IN MEDICINAL MANUFACTURE THEREOF | Jikai Biosciences, Inc. | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284363-A1 | PYRIDINE DERIVATIVES AS PIM KINASE INHIBITORS AND PREPARATION METHODS AND USE IN MEDICINAL MANUFACTURE THEREOF | PIM1, PIM2, PIM3 | PIM2 2/4885PIM1 1/4885PIM3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.